Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2631 - 2631
Published: Nov. 17, 2024
Despite the great advances in basic research results, glioblastoma multiforme (GBM) still remains an incurable tumour. To date, a GBM diagnosis is death sentence within 15-18 months, due to high recurrence rate and resistance conventional radio- chemotherapy approaches. The effort scientific community lavishing on never-ending battle against reflected by huge number of clinical trials launched, about 2003 10 September 2024. However, we are far from both in-depth comprehension biological molecular processes leading onset progression and, importantly, cure. provided with intratumoral heterogeneity, immunosuppressive capacity, infiltrative ability neoangiogenesis. These features impact tumour aggressiveness therapeutic vulnerability, which further limited presence core niches stem cells (GSCs) that responsible for relapse this brain neoplasm. Epigenetic alterations may drive develop along also rely changes expression genes encoding histone-modifying enzymes, including histone deacetylases (HDACs). Among them, HDAC6-a cytoplasmic HDAC-has recently gained attention because its role modulating several aspects GBM, DNA repair ability, massive growth, chemoresistance, de-differentiation through primary cilia disruption. In review article, available information related HDAC6 function will be presented, aim proposing inhibition as valuable route deadly
Language: Английский